What's in Vastra Gotaland Region's pipeline?

Vastra Gotaland Region has 24 drugs in our index: 6 marketed, 0 filed, 5 in Phase 3, 3 in Phase 2, 10 in Phase 1.

Which companies overlap with Vastra Gotaland Region's portfolio?

Top competitors by shared drug class: Baxter Healthcare Corporation, Bayer, Coalition for National Trauma Research, Erasmus Medical Center, Iwate Medical University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/vastra-gotaland-region.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Vastra Gotaland Region — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vastra Gotaland Region pipeline: 6 marketed, 0 filed, 5 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

6 marketed 0 filed 5 Phase 3 3 Phase 2 10 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Bisoprolol Oral Tablet	Bisoprolol Oral Tablet	marketed
Dry plasma	Dry plasma	marketed	Blood product / Plasma derivative		Hematology / Hemostasis
Dapagliflozin Oral Product	Dapagliflozin Oral Product	marketed
Ramipril Oral Product	Ramipril Oral Product	marketed
Progesterone vaginal tablet	Progesterone vaginal tablet	marketed
Dipyridamole 200 mg	Dipyridamole 200 mg	marketed
IPI3/NIVO1	IPI3/NIVO1	phase 3	ICOS agonist + PD-1 inhibitor combination	ICOS and PD-1	Oncology
Randomisation course 2 ADxE versus FLADx	Randomisation course 2 ADxE versus FLADx	phase 3			Immunology
IPI1/NIVO3	IPI1/NIVO3	phase 3	Checkpoint inhibitor combination (ICOS agonist + PD-1 inhibitor)	ICOS and PD-1	Oncology
busulfan, cyclophosphamide and melphalan, BuCyMel	busulfan, cyclophosphamide and melphalan, BuCyMel	phase 3
clofarabine, fludarabine and busulfan, CloFluBu	clofarabine, fludarabine and busulfan, CloFluBu	phase 3	Chemotherapy combination (nucleoside analogs + alkylating agent)	DNA synthesis and repair pathways; ribonucleotide reductase; DNA polymerase	Oncology

Therapeutic area mix

Oncology · 5
Hematology / Hemostasis · 1
Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Baxter Healthcare Corporation · 1 shared drug class
Bayer · 1 shared drug class
Coalition for National Trauma Research · 1 shared drug class
Erasmus Medical Center · 1 shared drug class
Iwate Medical University · 1 shared drug class
Jiangsu Simcere Pharmaceutical Co., Ltd. · 1 shared drug class
Rigshospitalet, Denmark · 1 shared drug class
Rutgers, The State University of New Jersey · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Vastra Gotaland Region:

Cite this brief

Drug Landscape (2026). Vastra Gotaland Region — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/vastra-gotaland-region. Accessed 2026-05-17.